CLINICAL TRIALS PROFILE FOR UPNEEQ
✉ Email this page to a colleague
All Clinical Trials for UPNEEQ
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT04831047 ↗ | The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance | Recruiting | University of Miami | Phase 4 | 2021-06-08 | The purpose of the research is to see if Upneeq ( oxymetazoline 0.1% ophthalmic solution) has an effect on eyelid position, eye redness, or patient-perceived appearance of the eyes. |
| NCT05945615 ↗ | Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis | Enrolling by invitation | Milton S. Hershey Medical Center | Phase 3 | 2024-01-11 | After an episode of facial paralysis, as nerves recover, they aberrantly regenerate and send additional branches to the incorrect muscles in addition to the intended muscle. This leads to what is known as Aberrant Regeneration Syndrome, Post-paralysis Synkinesis, or Nonflaccid Facial Paralysis. It is characterized by poor facial symmetry and function, hypertonic facial muscles at rest, and abnormal facial movements. One sequela is acquired blepharoptosis causing a smaller ocular aperture, visual field obstruction, cosmetic deformity, and abnormal periocular spasms. This study aims to evaluate an FDA approved medication for acquired blepharoptosis due to synkinesis/hyperkinesis as an adjunct to treatment. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for UPNEEQ
Condition Name
Clinical Trial Locations for UPNEEQ
Trials by Country
Clinical Trial Progress for UPNEEQ
Clinical Trial Phase
Clinical Trial Sponsors for UPNEEQ
Sponsor Name
